Senator Bernie Sanders Challenges Novo Nordisk's Pricing of Ozempic and Wegovy

Senator Bernie Sanders Grills Novo Nordisk CEO

During a Senate Health Committee hearing, U.S. Senator Bernie Sanders expressed serious concerns regarding high drug prices of Ozempic and Wegovy. Sanders highlighted that these medications, crucial for diabetes and obesity treatment, are excessively priced in the U.S.

Unacceptable Cost Disparities

• Ozempic's price in the U.S. is $969, while it is only $59 in Germany.
• Wegovy costs $1,349 in the U.S., compared to $92 in the United Kingdom.

Sanders stated, “If not made affordable, Americans throughout this country will needlessly die and suffer.” During the session, Senators pressed Lars Jorgensen, Novo Nordisk's CEO, urging him to treat the American people equitably.

Company’s Defense and Future Actions

In response, Jorgensen claimed that the price of Ozempic has decreased by 40% since its launch in 2018. He emphasized that 99% of commercial insurance plans cover Ozempic and that negotiations for broader coverage for Wegovy are ongoing.

• 80% of insured Americans can access these medications for $25 or less monthly.
• Concerns about inflation and demand for specialty drugs influencing pricing were noted.

Sanders contended that a significant portion of revenue generated by Novo Nordisk comes from the U.S., indicating a need for reform to benefit patients.

For further insights, refer to the original discussions from the Senate Health Committee.